{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:00:35Z","timestamp":1790452835500,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"H2020","doi-asserted-by":"publisher","award":["874753"],"award-info":[{"award-number":["874753"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.05.011","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:46:50Z","timestamp":1779853610000},"page":"877-881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluation of CFTR modulator therapies in cystic fibrosis: a cost-benefit and cost-effectiveness perspective from the REMEDIA European commission project"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0139-4166","authenticated-orcid":false,"given":"Ariel","family":"Beresniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Daruich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu Patrice","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Niddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Juusti-Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bremond-Gignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.jcf.2026.05.011_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"9358","key":"10.1016\/j.jcf.2026.05.011_bib0002","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"36","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"issue":"9678","key":"10.1016\/j.jcf.2026.05.011_bib0003","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.011_bib0004","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5694\/mja11.10719","article-title":"Cystic fibrosis in Australia, 2009: results from a data registry","volume":"195","author":"Bell","year":"2011","journal-title":"Med J Aust"},{"issue":"18","key":"10.1016\/j.jcf.2026.05.011_bib0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2026.05.011_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.05.011_bib0007","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.011_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.011_bib0009","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.011_bib0010","article-title":"A Comparative analysis of pricing and reimbursement of cystic fibrosis transmembrane conductance regulator modulators in Europe","volume":"8","author":"Abdallah","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.011_bib0011","first-page":"276","article-title":"The effectiveness and value of novel treatments for cystic fibrosis","volume":"27","author":"Tice","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.011_bib0012","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.3214","article-title":"Pharmacokinetic enhancement of CFTR modulators for global access","volume":"115","author":"Hong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.011_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40273-014-0216-0","article-title":"Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project","volume":"33","author":"Beresniak","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.011_bib0014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737167.2016.1184975","article-title":"Is there an alternative to quality-adjusted life years for supporting healthcare decision making?","volume":"16","author":"Beresniak","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jcf.2026.05.011_bib0015","article-title":"A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe","volume":"Nov 8","author":"Abdallah","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.011_bib0016","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.011_bib0017","first-page":"594","article-title":"Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents","volume":"71","author":"Whan Lee","year":"2008","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.011_bib0018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-018-0914-3","article-title":"Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States","volume":"13","author":"Sharma","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"Jan,8","key":"10.1016\/j.jcf.2026.05.011_bib0019","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"1","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.011_bib0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ccm.2022.07.002","article-title":"Update on Lung Transplantation for Cystic Fibrosis","volume":"43","author":"Pilewski","year":"2022","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.011_bib0021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0272-5231(05)70387-7","article-title":"The cost of lung transplantation and the quality of life post-transplant","volume":"18","author":"Gross","year":"1997","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2026.05.011_bib0022","doi-asserted-by":"crossref","unstructured":"Danzon PM, Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.. Value Health. 21(3): p. 252-257.","DOI":"10.1016\/j.jval.2017.12.018"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:49:42Z","timestamp":1790452182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326001347"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of CFTR modulator therapies in cystic fibrosis: a cost-benefit and cost-effectiveness perspective from the REMEDIA European commission project","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}